This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
CVS Health (CVS) Q4 Earnings Beat Estimates, '18 View Upbeat
by Zacks Equity Research
A strong Pharmacy Services segment, benefiting from the upside in the specialty services Drives CVS Health's (CVS) topline in Q4.
Cardinal Health (CAH) Beats on Q2 Earnings, Raises '18 View
by Zacks Equity Research
Solid performance at the Medical Segment drove Cardinal Health (CAH) in Q2.
Nielsen (NLSN) Q4 Earnings Up Y/Y, Revenues Match Estimates
by Zacks Equity Research
Nielsen (NLSN) delivers strong fourth-quarter profits driven by strength in Watch segment. Weakness in the U.S. Buy segment continues to be a concern.
Cardiovascular Systems (CSII) Q2 Earnings Top, Revenues Lag
by Zacks Equity Research
Cardiovascular Systems (CSII) witnesses year-over-year increase in Q2 revenues on strength in both the segments.
STERIS (STE) Q3 Earnings Beat & Revenues Miss, Margins Up
by Zacks Equity Research
STERIS (STE) witnesses year-over-year rise in Q3 revenues on favorable underlying market trends along with new product and service offerings.
The Zacks Analyst Blog Highlights: Capital City Bank, HCA, MSCI, PetMed and Saia
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Capital City Bank, HCA, MSCI, PetMed and Saia
Cerner (CERN) Misses Q4 Earnings Estimates, Bookings Soar
by Zacks Equity Research
Despite a decline in earnings year over year, all-time high bookings drive Cerner's (CERN) top line in Q4.
5 Top Stocks to Buy During This Bull & Bear Tug-of-War
by Tirthankar Chakraborty
While bullish investors show optimism on corporate earnings and prospects of tax cut, those with a bearish view fear that the Fed's embarking on a quicker route to interest rate hikes might derail the record bull run.
Haemonetics' (HAE) Q3 Earnings Top Estimates, EPS View Up
by Zacks Equity Research
Continued momentum in new business generation and geographical expansions drive Haemonetics (HAE) in the third quarter.
Myriad Genetics (MYGN) Beats on Earnings & Revenues in Q2
by Zacks Equity Research
Myriad Genetics' (MYGN) year over year decline in revenue was in Q2 is disappointing. However, strong demand for GeneSight tests was encouraging.
PetMed Express, Beazer Homes, Taylor Morrison, iRobot and NVIDIA as Zacks Bull and Bear of the Day
by Zacks Equity Research
PetMed Express, Beazer Homes, Taylor Morrison, iRobot and NVIDIA as Zacks Bull and Bear of the Day
Top Stock Picks for the Week of February 5th
by Brian Bolan
Two Stocks That Have Attractive Qualities for Investors.
LabCorp (LH) Q4 Earnings Beat Estimates, '18 View Promising
by Zacks Equity Research
LabCorp's (LH) Covance Drug Development of late begins to gain traction from Chiltern acquisition, strong organic growth and a favorable foreign currency translation.
AmerisourceBergen (ABC) Beats on Q1 Earnings, FY18 View Up
by Zacks Equity Research
Strong Growth in Pharmaceutical Distribution Segment and World Courier business drove AmerisourceBergen (ABC) in Q1.
Phibro Animal (PAHC) Beats on Q2 Earnings, Raises Guidance
by Zacks Equity Research
Phibro (PAHC) witnesses year-over-year improvement across all segments in Q2.
Becton, Dickinson (BDX) Beats on Q1 Earnings, Guidance Solid
by Zacks Equity Research
Strong growth in BD Medical and BD Life sciences segments drove Becton, Dickinson's (BD) top line in Q1.
Top Ranked Growth Stocks to Buy for February 6th
by Zacks Equity Research
Here are four stocks with buy ranks and strong growth characteristics for investors to consider today, February 6th:
Bull Of The Day PetMed Express (PETS)
by Brian Bolan
A solid earnings report and a lawsuit dismissal could make the shorts turn tail on this stock.
athenahealth (ATHN) Tops Earnings & Revenue Estimates in Q4
by Zacks Equity Research
Strong growth in Business and Services segment drove athenahealth's (ATHN) top line in Q4.
Omnicell (OMCL) Earnings Beat, Revenues Miss Estimates in Q4
by Zacks Equity Research
Omnicell's (OMCL) year-over-year growth at both the segments in Q4 is encouraging.
ABIOMED (ABMD) Beats Earnings and Revenue Estimates in Q3
by Zacks Equity Research
ABIOMED (ABMD) rides high on record revenues from Impella in third-quarter fiscal 2018. The company is also well poised with new accomplishments.
Pacific Biosciences (PACB) Q4 Loss Narrows, Consumables Up
by Zacks Equity Research
Pacific Biosciences' (PACB) consumable revenue platform proves a vital growth-driver in Q4. Sales momentum in China remains robust.
Edwards Lifesciences (EW) Beats on Q4 Earnings and Revenues
by Zacks Equity Research
Edwards Lifesciences (EW) gains from strength in THVT on continued therapy adoption across all geographies in Q4.
Alibaba (BABA) Q3 Earnings Lag Estimates, Revenues Grow Y/Y
by Zacks Equity Research
Alibaba Group Holding Limited (BABA) fiscal third-quarter revenues driven by strong momentum in the company's New Retail strategy and expanding cloud business. Higher expenses hurt profits.
Alphabet (GOOGL) Q4 Earnings Miss Estimates, Revenues Beat
by Zacks Equity Research
Alphabet Inc. (GOOGL) delivers strong fourth quarter top line numbers on robust advertising and cloud revenues. However, increased expenditure on new activities impacted profits.